March 11, 2020
QuaCell Biotechnology completes a new round of financing｜Introduction of our Strategic Investor Shenzhen Capital Group CO., LTD.
QuaCell Biotechnology, Co., Ltd. (hereinafter referred to as "QuaCell"), announced the completion of a new round of financing and the introduction of strategic investor Shenzhen Innovation Investment Group Co., Ltd. ("Shenzhen Venture Capital"). Before this, QuaCell has completed multiple rounds of financing. Investors include Queshan Investment, Publics Venture Capital, Xiangshang Investment, and Taikang Asset Management. This round of financing introduces the senior investment institution Shenzhen Capital Group as a strategic investor to provide resources and assistance for QuaCell to formulate future strategies, cooperate with upstream and downstream companies that have invested, and jointly promote the rapid development of QuaCell.
H.Fai Poon, CEO of QuaCell, and Wu Fan, COO of QuaCell, said that QuaCell Bio had achieved close cooperation with many domestic and foreign biopharmaceutical companies past two years and customers have widely recognized our products and R&D capabilities. In this round, Shenzhen Capital Group was introduced as the company's strategic investor. We believe that its large upstream and downstream companies in the invested biopharmaceutical industry can have more diversified cooperation with QuaCell.
Lin Yunyu, the Senior Investment Manager of Shenzhen Capital Group, believes that QuaCell focuses on the R&D and manufacturing of core raw materials for biopharmaceutical production, and the team has strong R&D capabilities. The current global epidemic is raging, public health awareness is further strengthened, and the effect of "domestic substitution" is obvious. Therefore, for domestic biopharmaceuticals and their industrial chain, opportunities and challenges coexist. They firmly invest in QuaCell and firmly believe that QuaCell provides a "sharp sword" for domestic biopharmaceuticals' rapid development.
Dr. Poon, CEO of QuaCell Biotechnology, Co., Ltd. was honored to be elected Associate Editor of RE: GEN Open
Conclusion | Biofuture2021
BIG EVENETS. Day 2 | Biofuture 2021
BIG EVENETS. Day 1 | Biofuture 2021
Wayne293™ Transient medium was launched